Lipegfilgrastim

DB13200ApprovedProtein Based Therapies

Lipegfilgrastim is a medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology.

Protein structure of Lipegfilgrastim
Mechanism
Curator reviewed · 6 references
Primary indication
Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).Curator reviewed · 2 structured indications
Formula / weight
C866H1372N226O258S9*(C2H4O)n · 39000.0 Da (glycoPEGylated, approximate)
First approval
European Union, 2016
Code names
XM-22
Brand names
  • Lonquex

Resolves to

What you can answer from here — as of January 20, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
156Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
13Marketed productsAcross 5 countries and 4 labellers
Sign in
1ATC codeIncluding every combination product, plus 20 drug categories
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lipegfilgrastim, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account